Abstract

This Program Project will continue to investigate Photodynamic Therapy (PDT) as applied to solid tumor therapy. The clinical applications will focus on malignant brain tumors and prostate cancer. The four projects will cover research topics ranging from basic molecular and cellular responses to PDT to the conduct of novel clinical trials employing PDT. The projects are supported by two cores that are integral to the overall success of the Program. The synergy of the Program will continue to depend upon the effective interactions between both the scientific and clinical projects and the investigators. Project 1 will investigate in preclinical models novel strategies for the improved treatment of brain tumors. This project will incorporate aim one from prior Project 4 examining and comparing the molecular effects of ALA-mediated metronomic PDT versus acute ALA-mediated PDT in brain tumor. Project 2 consists of both ongoing and new clinical trials for the treatment of brain tumors. Project 3 will investigate in canine and murine models the possible use of PDT for the treatment of prostate tumors employing a novel, second-generation sensitizer, Tookad. Project 5 (not renumbered) will focus on the development of new biophysical techniques for monitoring PDT in vivo and on translating already developed methods and devices into clinical applications. Core 1 will provide the necessary administrative support for the overall Program and Core 2 will provide technical support to all of the preclinical and clinical projects.

  Funding Agency

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Program Projects (P01)
Project #
2P01CA043892-14A2
Application #
6817708
Study Section
Subcommittee G - Education (NCI)
Program Officer
Stone, Helen B
Project Start
1999-01-01
Project End
2008-12-31
Budget Start
2004-07-20
Budget End
2004-12-31
Support Year
14
Fiscal Year
2004
Total Cost
$754,688
Indirect Cost

  Institution

Name
Healthone Alliance
Department
Type
DUNS #
098407869
City
Denver
State
CO
Country
United States
Zip Code
80203

  Publications

Wang, Luo-Wei; Huang, Zheng; Lin, Han et al. (2013) Effect of Photofrin-mediated photocytotoxicity on a panel of human pancreatic cancer cells. Photodiagnosis Photodyn Ther 10:244-251
Lei, Tim C; Pendyala, Srinivas; Scherrer, Larry et al. (2013) Optical profiles of cathode ray tube and liquid crystal display monitors: implication in cutaneous phototoxicity in photodynamic therapy. Appl Opt 52:2711-7
Weston, Mark A; Patterson, Michael S (2011) Calculation of singlet oxygen dose using explicit and implicit dose metrics during benzoporphyrin derivative monoacid ring A (BPD-MA)-PDT in vitro and correlation with MLL cell survival. Photochem Photobiol 87:1129-37
Santra, Manoranjan; Zheng, Xuguang; Roberts, Cindi et al. (2010) Single doublecortin gene therapy significantly reduces glioma tumor volume. J Neurosci Res 88:304-14
Singh, Gurmit; Alqawi, Omar; Espiritu, Myrna (2010) Metronomic PDT and cell death pathways. Methods Mol Biol 635:65-78
Zheng, Xuguang; Jiang, Feng; Katakowski, Mark et al. (2009) ADAM17 promotes breast cancer cell malignant phenotype through EGFR-PI3K-AKT activation. Cancer Biol Ther 8:1045-54
Hong, Xin; Jiang, Feng; Kalkanis, Steven N et al. (2009) Intracellular free calcium mediates glioma cell detachment and cytotoxicity after photodynamic therapy. Lasers Med Sci 24:777-86
Santra, Manoranjan; Santra, Sutapa; Roberts, Cindi et al. (2009) Doublecortin induces mitotic microtubule catastrophe and inhibits glioma cell invasion. J Neurochem 108:231-45
Gullo, Francesca; Maffezzoli, Andrea; Dossi, Elena et al. (2009) Short-latency cross- and autocorrelation identify clusters of interacting cortical neurons recorded from multi-electrode array. J Neurosci Methods 181:186-98
Szalad, Alexandra; Katakowski, Mark; Zheng, Xuguang et al. (2009) Transcription factor Sp1 induces ADAM17 and contributes to tumor cell invasiveness under hypoxia. J Exp Clin Cancer Res 28:129

Showing the most recent 10 out of 81 publications